A

AbbVie

Global biopharmaceutical company developing medicines

Head of Marketing - Retina Eye Care

Full-TimeUpdated on 10/23/2026
$182k - $346k/yr+ Long-term incentive program
Expert
Bachelor's, MBA
Mattawa, WA, USA
HybridHybrid work arrangement; travel as required, approximately 35%.
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A bachelor's degree is required.
  • A minimum of 10 years of marketing experience is required.
  • Extensive progressive pharmaceutical, biotechnology, or specialty-care commercial experience is required, including significant leadership in marketing and brand strategy.
  • Demonstrated success leading a franchise, portfolio, or major brand across multiple life-cycle stages, including launch planning and in-market growth, is required.
  • Strong people-leadership experience is required, with a record of building high-performing teams, developing talent, and leading through change in a matrixed organization.
  • Deep expertise across the marketing capability framework is required, including insights, segmentation, positioning, value proposition, customer experience, creative development, omnichannel execution, and investment optimization.
  • Strong financial and analytical acumen is required, including forecasting, operating-budget management, resource allocation, performance measurement, and P&L-oriented decision making.
  • The ability to lead and influence senior cross-functional stakeholders across Sales, Market Access, Medical Affairs, Regulatory, Legal, Compliance, Finance, Operations, R&D, and Global teams is required.
  • Excellent executive communication, strategic problem solving, judgment, and decision-making skills are required, along with the ability to translate complexity into clear direction and action.
  • The ability to travel as required, approximately 35%, is required.
Responsibilities
  • Set the overarching Retina Marketing strategy across in-line and pipeline assets, ensuring strategies reflect enterprise priorities, customer needs, market dynamics, and asset life-cycle considerations.
  • Own marketing inputs to the Retina business plan, including forecast assumptions, operating budgets, resource allocation, performance objectives, and investment trade-offs.
  • Direct the development, execution, measurement, and optimization of integrated marketing plans; establish performance indicators, identify risks and opportunities, and hold the organization accountable for timely, high-quality delivery and business results.
  • Lead, coach, and develop direct and indirect team members; set clear priorities, roles, and decision rights; and foster a high-performing culture grounded in trust, accountability, agility, collaboration, and enterprise leadership.
  • Lead commercial strategy and readiness for launch products, including go-to-market planning, positioning, customer and site-of-care readiness, distribution, and access considerations; ensure continued optimization of established brands.
  • Maintain a deep understanding of retina specialists, patients, practices, sites of care, health care decision makers, and competitive dynamics.
  • Serve as the senior Marketing representative for Retina, aligning Sales, Market Access, Medical Affairs, Regulatory, Legal, Compliance, Finance, Operations, Trade, Supply Chain, Patient Services, Analytics, R&D, and Global around shared priorities, decisions, resourcing, and execution.
  • Oversee agency and vendor partnerships and guide appropriate engagement with external collaborators, professional societies, and advocacy organizations.
  • Provide clear recommendations, updates, and decision frameworks to broader AbbVie leadership; influence and communicate across the organizational matrix.
  • Ensure all strategies and activities comply with AbbVie policies and applicable legal, regulatory, medical, and industry requirements.
Desired Qualifications
  • An MBA or other advanced degree is preferred.
  • Experience in ophthalmology, retina, buy-and-bill, specialty biologics, site-of-care markets, or physician-administered therapies is preferred.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.

Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.